Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.

Bi XC, Liu JM, Zheng XG, Xian ZY, Feng ZW, Lou YX, Zhong WD, Wu CL.

Clin Invest Med. 2011 Dec 1;34(6):E358.

PMID:
22129926
2.

Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.

Gomella LG, Raj GV, Moreno JG.

J Urol. 1997 Aug;158(2):326-37. Review.

PMID:
9224297
3.

Do we use the right criteria for determining the clinical significance of incidental prostate cancer at radical cystoprostatectomy?

Gakis G, Stenzl A, Renninger M.

Scand J Urol. 2013 Oct;47(5):358-62. doi: 10.3109/00365599.2012.723045. Epub 2012 Oct 18. Review.

PMID:
23078550
4.

Future prospects in the diagnosis and management of localized prostate cancer.

Tefekli A, Tunc M.

ScientificWorldJournal. 2013 Sep 14;2013:347263. doi: 10.1155/2013/347263. eCollection 2013. Review.

PMID:
24163619
5.

EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects.

Liu DT.

Tumour Biol. 2015 Jul;36(7):4883-8. doi: 10.1007/s13277-015-3544-6. Epub 2015 May 14. Review.

PMID:
25967458

Supplemental Content

Write to the Help Desk